Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients
Oncology · 2024
DOI: 10.1159/000540334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Mert Erciyestepe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sağlık Bilimleri University, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Colonic Neoplasms, Neoplasm Recurrence, Local, Neoplasm Staging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Our study delves into the intricate interplay of risk factors and the strategic selection of adjuvant therapy, scrutinizing their influence on recurrence and survival outcomes in stage IIA (T3N0M0) colon cancer patients. Materials and Methods: The study examined the medical records of patients who underwent surgery for stage IIA colon cancer. Identification of stage IIA (pT3N0M0) colon cancer involved a comprehensive review of postoperative clinical records and histological reports. Parameters such as demographic data, tumor characteristics, microsatellite instability status, tumor locations, recurrence risk factors, preoperative carcinoembryonic antigen levels, and adjuvant treatments were systematically evaluated.
Results
In our study involving 220 patients, 138 were male (62.7%), with a median age of 62 years and a median body mass index of 25.1 kg/m2. In the patient group without risk factors, no statistically significant difference was detected in disease-free survival (DFS) rates between those who received treatment and those who did not (p = 0.546). DFS rates of patients with >1 risk factor were statistically significantly lower than those with a single risk factor (p = 0.017). In patients with >1 risk factor, the DFS of those who did not receive adjuvant treatment was significantly lower than those who received adjuvant treatment (p < 0.001). In the patient group with recurrence, when adjuvant treatments were considered, recurrence was significantly higher in the group receiving capecitabine (p = 0.01).
Conclusion
The decision for adjuvant chemotherapy in stage IIA colon cancer patients involves careful consideration of various parameters and risk factors. The evolving landscape of research may refine recommendations, ensuring optimal treatment outcomes while minimizing unnecessary toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sağlık Bilimleri University, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.
- Department of Medical Oncology, Celal Bayar University, Manisa, Turkey.
Zitieren
APA
Erciyestepe, M., Selvi, O., Dinç, G., Öztürk, A. E., Aydın, O., Dinç Sonuşen, Ş., Güneş, T. K., Avcı, T., Vatansever, S., Çelik, E., & Atcı, M. M. (2024). Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients. Oncology. https://doi.org/10.1159/000540334
Vancouver
Erciyestepe M, Selvi O, Dinç G, Öztürk AE, Aydın O, Dinç Sonuşen Ş, et al. Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients. Oncology. 2024. doi:10.1159/000540334
BibTeX
@article{Erciyestepe2024,
author = {Erciyestepe, Mert and Selvi, Oğuzhan and Dinç, Gülhan and Öztürk, Ahmet Emin and Aydın, Okan and Dinç Sonuşen, Şermin and Güneş, Tuğçe Kübra and Avcı, Tugay and Vatansever, Sezai and Çelik, Emir and Atcı, Muhammed Mustafa},
title = {Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540334}
}
EUVIMED